NEUREN PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.34 AUD | +5.64% |
|
+6.17% | -14.54% |
| 05-09 | Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million | MT |
| 04-24 | Neuren Pharmaceuticals Posts AU$243 Million Cash, Short-Term Investments | MT |
Evolution of the average Target Price on Neuren Pharmaceuticals Limited
Price target over the last 5 years
History of analyst recommendation changes
09e98e39a76cf2e65cf1a76e60e36.HMm2J4uSOOdUbrtgQ9ElvM8N3Jev8ghabvawoV2YK7s.Q7rRXdz6fIUHANg3FY5wxJpVlv7Mp0oRKZPq6gfUbfF48ccT-6d-gDcMgw~c49e69e620e0e3d8733d42e87f26dddd
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
20.2
AUD
Average target price
26.13
AUD
Spread / Average Target
+29.36%
High Price Target
31
AUD
Spread / Highest target
+53.47%
Low Price Target
22.8
AUD
Spread / Lowest Target
+12.87%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
D+
EPS Revisions
- Stock Market
- Equities
- NEU Stock
- Consensus Neuren Pharmaceuticals Limited
